{
    "clinical_study": {
        "@rank": "67219", 
        "arm_group": [
            {
                "arm_group_label": "Pharmacokinetic profiling in Hemodialysis", 
                "arm_group_type": "Experimental", 
                "description": "Patients with chronic intermittent hemodialysis receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn."
            }, 
            {
                "arm_group_label": "Pharmacokinetic profiling in CVVH", 
                "arm_group_type": "Experimental", 
                "description": "Patients receiving continuous venovenous renal replacement therapy in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn."
            }, 
            {
                "arm_group_label": "Pharmacokinetic profiling in MARS", 
                "arm_group_type": "Experimental", 
                "description": "Patients receiving liver replacement therapy (MARS) in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn."
            }
        ], 
        "brief_summary": {
            "textblock": "The study is conducted to investigate the pharmacokinetics of Doripenem during CVVHDF\n      (Continuous venovenous hemodiafiltration), MARS (Molecular Adsorbent Recirculating System)\n      and intermittent hemodialysis."
        }, 
        "brief_title": "Multiple-dose Pharmacokinetics of Doripenem During Continuous Venovenous Hemodiafiltration and Molecular Adsorbent Recirculating System in ICU Patients and During Hemodialysis in Longterm Hemodialysis Patients.", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Infections During Organ Replacement Therapy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age >18 years\n\n          -  Suspected or proven bacterial infection requiring parenteral antibiotic therapy.\n\n          -  Organ replacement therapy (MARS, CVVHDF or HD)\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity to doripenem or other carbapenems, or severe hypersensitivity\n             (anaphylactic reaction) to beta-lactam antibacterial agents.\n\n          -  An expected survival of less than two days.\n\n          -  Known pregnancy\n\n          -  Coadministration of valproic acid or probenecid, which cannot be discontinued for the\n             duration of the study\n\n          -  Doripenem as monotherapy for resistent species or fungal infections.\n\n          -  Other reasons opposing the study participation on the discretion of the\n             investigators."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02018939", 
            "org_study_id": "DORIPENEM IN CVVH, MARS AND HD"
        }, 
        "intervention": {
            "arm_group_label": [
                "Pharmacokinetic profiling in Hemodialysis", 
                "Pharmacokinetic profiling in CVVH", 
                "Pharmacokinetic profiling in MARS"
            ], 
            "description": "Pharmacokinetic samples are taken from each Patient receiving Doripenem in each arm. No other interventions are performed during this trial. Doripenem is not administered due to the trial.", 
            "intervention_name": "Pharmacokinetic profiling", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "pharmacokinetics, doripenem, renal replacement therapy, MARS, organ replacement therapy", 
        "lastchanged_date": "March 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Vienna", 
                    "country": "Austria", 
                    "zip": "1090"
                }, 
                "name": "Medical University of Vienna"
            }
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "3", 
        "official_title": "Multiple-dose Pharmacokinetics of Doripenem During Continuous Venovenous Hemodiafiltration and Molecular Adsorbent Recirculating System in ICU Patients and During Hemodialysis in Longterm Hemodialysis Patients.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Austria: Federal Office for Safety in Health Care", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Pharmacokinetic samples are drawn from each patient during the trial. Analysis by HPLC will be conducted after the end of the trial.", 
            "measure": "Influence of organ replacement therapy on area under curve of doripenem serum concentration", 
            "safety_issue": "No", 
            "time_frame": "day 15"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02018939"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of Vienna", 
            "investigator_full_name": "Florian Thalhammer", 
            "investigator_title": "a.o.Univ.-Prof. Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Medical University of Vienna", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of Vienna", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2010", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}